// App-Quantinova.ai

: Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT.

Researchers

Presenter

  • Ray Manneh Kopp

Principal Investigators

  • Carmen Alaez Verson

  • Martin Angel

  • Arturo Delgado

  • Pedro H Isaacsson Velho

  • Alejandro Manduley

  • Melissa Barbieri

  • Carmen Vargas

  • Francisco Gonzalez

  • Pedro C. Barata

Medical Centers

  • Instituto Alexander Fleming, CABA, Argentina

  • Astra Zeneca AG, Baar, Switzerland

  • Centro Médico Nacional Siglo XXI, Ciudad De México, Mexico

  • Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia

  • Tulane Medical School, New Orleans, LA

  • Astra Zeneca, Cambridge, United Kingdom

  • Instituto Nacional de Medicina Genómica, Ciudad De México, Mexico

  • Hospital Moinhos De Vento, Porto Alegre, RS, Brazil

  • Centro de Especialidades Urológicas de Panamá, Panama City, Panama

  • AstraZeneca Central America and Caribbean, San Jose, Costa Rica

Locations

  • Colombia

  • Argentina

  • United States

  • Costa Rica

  • Panama

  • Switzerland

  • United Kingdom

  • Brazil

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

  • Hormone receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

  • Multicenteric

  • Cross-Sectional

Phase

  • NA

Study Id's

  • NCT04962880

  • NCT02987543

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved